B.Riley analyst Madison El-Saadi initiates coverage on Compass Pathways (NASDAQ: CMPS) with a Buy rating and a price target of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage

TD Cowen on Compass Pathways (CMPS) FDA Grant: 'meaningful positive and expected in light of last Saturday’s Executive Order'April 24, 2026 3:41 PM Oppenheimer on Compass Pathways (CMPS) FDA Grant: 'reinforcing our conviction considering the earlier launch timeline for COMP360 in TRD'April 24, 2026 1:24 PM Morgan Stanley on Compass Pathways (CMPS): 'we view today’s update as incrementally encouraging'April 24, 2026 1:06 PM